This company has been marked as potentially delisted and may not be actively trading. NASDAQ:ALDR Alder Biopharmaceuticals (ALDR) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Alder Biopharmaceuticals Stock (NASDAQ:ALDR) Get ALDR alerts:Sign Up Key Stats Today's Range$18.88▼$18.8850-Day Range$18.88▼$18.8852-Week Range$8.39▼$19.12VolumeN/AAverage Volume5.12 million shsMarket Capitalization$1.58 billionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Alder BioPharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical company. It discovers, develops, and commercializes therapeutic antibodies to transform the treatment paradigm for patients with migraine in the United States, Australia, and Ireland. The company's lead product candidate is eptinezumab, a monoclonal antibody (mAb) inhibiting calcitonin gene-related peptide, which is in the late-stage clinical development for the prevention of migraine. It also develops ALD1910, a preclinical mAb that inhibits pituitary adenylate cyclase-activating polypeptide-38 for migraine prevention; and Clazakizumab, a mAb inhibiting the pro-inflammatory cytokine interleukin-6 that has completed two Phase 2b clinical trials. The company has strategic collaboration with CSL Limited for the development of clazakizumab as a therapeutic option for solid organ transplant rejection. Alder BioPharmaceuticals, Inc. was incorporated in 2002 and is headquartered in Bothell, Washington. Read More Receive ALDR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Alder Biopharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ALDR Stock News HeadlinesAlder Hey measles death: Liverpool's top health boss very worried spread of disease could spark health crisisJuly 17, 2025 | msn.comNew details released after child with measles dies at Alder HeyJuly 14, 2025 | msn.com1 Hour Once A DayMy top income trading expert, Dave Aquino, just released a 1-hour trading strategy designed specifically to help regular investors generate enough income to become financially independent… Without taking on excessive amounts of risk. I’m talking about having the opportunity to collect $500 on Monday… $563 on Wednesday… Then as much as $625 on Friday.October 10 at 2:00 AM | Base Camp Trading (Ad)Alder Hey's plea after child dies with measlesJuly 13, 2025 | msn.comChild with measles dies in Alder Hey as health officials fear outbreakJuly 13, 2025 | msn.comChild dies at Alder Hey after contracting measlesJuly 13, 2025 | bbc.comBMore children and young people at Alder Hey Children's Hospital waiting for mental health treatmentJuly 11, 2025 | msn.comAlder Hey Children's Hospital: how long patients waited for NHS treatment in MayJuly 10, 2025 | msn.comSee More Headlines ALDR Stock Analysis - Frequently Asked Questions How were Alder Biopharmaceuticals' earnings last quarter? Alder Biopharmaceuticals Inc (NASDAQ:ALDR) posted its earnings results on Tuesday, August, 7th. The biopharmaceutical company reported ($1.04) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.05) by $0.01. What other stocks do shareholders of Alder Biopharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Alder Biopharmaceuticals investors own include Bristol Myers Squibb (BMY), (CPXX) (CPXX), NVIDIA (NVDA), Celldex Therapeutics (CLDX), Meta Platforms (META), Gilead Sciences (GILD) and Micron Technology (MU). Company Calendar Last Earnings8/07/2018Today10/10/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNASDAQ:ALDR CIK1423824 Webwww.alderbio.com Phone425-205-2900FaxN/AEmployees202Year FoundedN/AProfitability EPS (Trailing Twelve Months)($4.87) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$296.43 million Net MarginsN/A Pretax MarginN/A Return on Equity-226.13% Return on Assets-66.86% Debt Debt-to-Equity Ratio1.74 Current Ratio8.94 Quick Ratio8.94 Sales & Book Value Annual Sales$1.62 million Price / Sales977.10 Cash FlowN/A Price / Cash FlowN/A Book Value$1.61 per share Price / Book11.73Miscellaneous Outstanding Shares83,840,000Free FloatN/AMarket Cap$1.58 billion OptionableOptionable Beta2.64 Elon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free Report This page (NASDAQ:ALDR) was last updated on 10/10/2025 by MarketBeat.com Staff From Our PartnersAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | Sponsored1 Hour Once A DayMy top income trading expert, Dave Aquino, just released a 1-hour trading strategy designed specifically to he...Base Camp Trading | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredWhy This Titanium Explorer Caught Rio Tinto’s EyeAs U.S. defense spending crosses $1 trillion, drones, hypersonics, and next-gen aerospace are taking center st...Capital Trends | SponsoredToo busy for AI trading?Last week, Nvidia and AMD stock soared as export restrictions eased. Nvidia alone gained nearly 5% in a sin...Timothy Sykes | SponsoredHave you heard of the Texas Royalty Plan?There is a backdoor way you could collect a check, four times a year, thanks to the exploding oil industry in ...Brownstone Research | SponsoredHow to Cash In on Trump’s Digital Current - Move By This ThursdayBitcoin Breakout: What Most Investors Are Missing Washington just approved more crypto legislation in 90 da...Investors Alley | SponsoredTesla’s $30 trillion pivotElon Musk says November 6 could "affect the future of the world" Get ready for the biggest pivot in corpora...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alder Biopharmaceuticals Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Alder Biopharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
